FDA Approves Drug for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to other parts of the body and continued to progress despite previous treatment. This marks a significant development for a disease with historically limited treatment options and poor survival rates. Experts at Moores Cancer Center at UC San Diego Health are available to discuss what this approval means for patients, how the therapy fits into current treatment approaches, and o